- Kiromic BioPharma Inc (NASDAQ:KRBP) has announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT.
- Kiromic expects to submit its first new investigational new drug (IND) application to the FDA in 2H of 2022.
- The IND will seek to evaluate Deltacel in combination with a standard antitumor modality, with the expected beginning of trial activation by year-end.
- Related: Why Kiromic Biopharma Shares Are Skyrocketing Today?
- Kiromic will also pursue INDs for its Procel and Isocel product candidates in combination with a standard antitumor modality in 2023.
- These three additional IND filings will expand the Company's pipeline to five allogeneic GDT clinical trials and three product candidates.
- Price Action: KRBP shares are up 14.60% at $0.46 during the market session on the last check Tuesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Kiromic BioPharma's Prioritizes New Gamma Delta T-Cell Product Candidate
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks